Coherus Oncology, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Coherus Oncology, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2018 | Dec 31, 2018 | $0 | Feb 28, 2019 |
| FY2018 | Dec 31, 2017 | $1.56M | Feb 28, 2019 |
| FY2018 | Dec 31, 2016 | $190.11M | Feb 28, 2019 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2019 | Dec 31, 2019 | $123.86M | Feb 27, 2020 |
| FY2019 | Sep 30, 2019 | $111.68M | Feb 27, 2020 |
| FY2019 | Jun 30, 2019 | $83.43M | Feb 27, 2020 |
| FY2019 | Mar 31, 2019 | $37.10M | Feb 27, 2020 |
| FY2019 | Dec 31, 2018 | $0 | Feb 27, 2020 |
| FY2019 | Sep 30, 2018 | $0 | Feb 27, 2020 |
| FY2019 | Jun 30, 2018 | $0 | Feb 27, 2020 |
| FY2019 | Mar 31, 2018 | $0 | Feb 27, 2020 |
| FY2018 | Dec 31, 2017 | $0 | Feb 28, 2019 |
| FY2018 | Sep 30, 2017 | $0 | Feb 28, 2019 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $1.56M | Mar 8, 2018 |
| FY2017 | Jun 30, 2017 | $1.40M | Mar 8, 2018 |
| FY2017 | Mar 31, 2017 | $161.0K | Mar 8, 2018 |
| FY2017 | Dec 31, 2016 | $844.0K | Mar 8, 2018 |
| FY2017 | Sep 30, 2016 | $162.84M | Mar 8, 2018 |
| FY2017 | Jun 30, 2016 | $14.07M | Mar 8, 2018 |
| FY2017 | Mar 31, 2016 | $12.36M | Mar 8, 2018 |
| FY2016 | Dec 31, 2015 | $10.20M | Mar 14, 2017 |
| FY2016 | Sep 30, 2015 | $7.17M | Mar 14, 2017 |
| FY2016 | Jun 30, 2015 | $6.87M | Mar 14, 2017 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2019 | Dec 31, 2019 | $116.05M | Feb 27, 2020 |
| FY2019 | Sep 30, 2019 | $105.24M | Feb 27, 2020 |
| FY2019 | Jun 30, 2019 | $82.83M | Feb 27, 2020 |
| FY2019 | Mar 31, 2019 | $34.87M | Feb 27, 2020 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $168.02M | Mar 9, 2026 |
| FY2025 | Dec 31, 2024 | $28.51M | Mar 9, 2026 |
| FY2024 | Dec 31, 2023 | ($237.89M) | Mar 17, 2025 |
| FY2024 | Dec 31, 2022 | ($291.75M) | Mar 17, 2025 |
| FY2023 | Dec 31, 2021 | ($287.10M) | Mar 15, 2024 |
| FY2022 | Dec 31, 2020 | $132.24M | Mar 6, 2023 |
| FY2021 | Dec 31, 2019 | $89.83M | Feb 23, 2022 |
| FY2019 | Dec 31, 2018 | ($62.60M) | Feb 27, 2020 |
| FY2019 | Sep 30, 2018 | ($58.81M) | Feb 27, 2020 |
| FY2019 | Jun 30, 2018 | ($43.64M) | Feb 27, 2020 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($181.13M) | Mar 9, 2026 |
| FY2025 | Dec 31, 2024 | ($199.65M) | Mar 9, 2026 |
| FY2024 | Dec 31, 2023 | ($203.20M) | Mar 17, 2025 |
| FY2024 | Dec 31, 2022 | ($256.88M) | Mar 17, 2025 |
| FY2023 | Dec 31, 2021 | ($263.86M) | Mar 15, 2024 |
| FY2022 | Dec 31, 2020 | $156.32M | Mar 6, 2023 |
| FY2021 | Dec 31, 2019 | $107.77M | Feb 23, 2022 |
| FY2020 | Dec 31, 2018 | ($204.42M) | Feb 25, 2021 |
| FY2019 | Dec 31, 2017 | ($232.14M) | Feb 27, 2020 |
| FY2018 | Dec 31, 2016 | ($115.93M) | Feb 28, 2019 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $108.89M | Mar 9, 2026 |
| FY2025 | Dec 31, 2024 | $91.83M | Mar 9, 2026 |
| FY2024 | Dec 31, 2023 | $109.44M | Mar 17, 2025 |
| FY2024 | Dec 31, 2022 | $199.36M | Mar 17, 2025 |
| FY2023 | Dec 31, 2021 | $363.11M | Mar 15, 2024 |
| FY2022 | Dec 31, 2020 | $142.76M | Mar 6, 2023 |
| FY2021 | Dec 31, 2019 | $94.19M | Feb 23, 2022 |
| FY2020 | Dec 31, 2018 | $110.24M | Feb 25, 2021 |
| FY2019 | Dec 31, 2017 | $162.39M | Feb 27, 2020 |
| FY2018 | Dec 31, 2016 | $254.44M | Feb 28, 2019 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $100.60M | Mar 9, 2026 |
| FY2025 | Dec 31, 2024 | $125.48M | Mar 9, 2026 |
| FY2024 | Dec 31, 2023 | $192.02M | Mar 17, 2025 |
| FY2024 | Dec 31, 2022 | $198.48M | Mar 17, 2025 |
| FY2023 | Dec 31, 2021 | $169.71M | Mar 15, 2024 |
| FY2022 | Dec 31, 2020 | $139.08M | Mar 6, 2023 |
| FY2021 | Dec 31, 2019 | $137.04M | Feb 23, 2022 |
| FY2020 | Dec 31, 2018 | $94.18M | Feb 25, 2021 |
| FY2019 | Dec 31, 2017 | $71.30M | Feb 27, 2020 |
| FY2018 | Dec 31, 2016 | $51.60M | Feb 28, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($138.51M) | Mar 9, 2026 |
| FY2025 | Dec 31, 2024 | ($20.44M) | Mar 9, 2026 |
| FY2024 | Dec 31, 2023 | ($174.88M) | Mar 17, 2025 |
| FY2024 | Dec 31, 2022 | ($241.12M) | Mar 17, 2025 |
| FY2023 | Dec 31, 2021 | ($37.43M) | Mar 15, 2024 |
| FY2022 | Dec 31, 2020 | $154.15M | Mar 6, 2023 |
| FY2021 | Dec 31, 2019 | $28.36M | Feb 23, 2022 |
| FY2020 | Dec 31, 2018 | ($159.27M) | Feb 25, 2021 |
| FY2019 | Dec 31, 2017 | ($200.29M) | Feb 27, 2020 |
| FY2018 | Dec 31, 2016 | ($252.55M) | Feb 28, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $286.0K | Mar 15, 2024 |
| FY2023 | Dec 31, 2022 | $2.04M | Mar 15, 2024 |
| FY2023 | Dec 31, 2021 | $1.29M | Mar 15, 2024 |
| FY2022 | Dec 31, 2020 | $7.23M | Mar 6, 2023 |
| FY2021 | Dec 31, 2019 | $1.82M | Feb 23, 2022 |
| FY2020 | Dec 31, 2018 | $789.0K | Feb 25, 2021 |
| FY2019 | Dec 31, 2017 | $4.57M | Feb 27, 2020 |
| FY2018 | Dec 31, 2016 | $6.52M | Feb 28, 2019 |
| FY2017 | Dec 31, 2015 | $6.16M | Mar 8, 2018 |
| FY2016 | Dec 31, 2014 | $2.85M | Mar 14, 2017 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $258.34M | Mar 9, 2026 |
| FY2025 | Dec 31, 2024 | $448.53M | Mar 9, 2026 |
| FY2024 | Dec 31, 2023 | $629.60M | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | $480.85M | Mar 15, 2024 |
| FY2022 | Dec 31, 2021 | $679.33M | Mar 6, 2023 |
| FY2021 | Dec 31, 2020 | $841.65M | Feb 23, 2022 |
| FY2020 | Dec 31, 2019 | $408.93M | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | $99.47M | Feb 27, 2020 |
| FY2018 | Dec 31, 2017 | $162.61M | Feb 28, 2019 |
| FY2017 | Dec 31, 2016 | $178.49M | Mar 8, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $197.33M | Mar 9, 2026 |
| FY2025 | Dec 31, 2024 | $580.52M | Mar 9, 2026 |
| FY2024 | Dec 31, 2023 | $823.03M | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | $618.27M | Mar 15, 2024 |
| FY2022 | Dec 31, 2021 | $581.61M | Mar 6, 2023 |
| FY2021 | Dec 31, 2020 | $560.68M | Feb 23, 2022 |
| FY2020 | Dec 31, 2019 | $303.71M | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | $138.06M | Feb 27, 2020 |
| FY2018 | Dec 31, 2017 | $132.08M | Feb 28, 2019 |
| FY2017 | Dec 31, 2016 | $159.13M | Mar 8, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $61.01M | Mar 9, 2026 |
| FY2025 | Dec 31, 2024 | ($131.99M) | Mar 9, 2026 |
| FY2025 | Dec 31, 2023 | ($193.43M) | Mar 9, 2026 |
| FY2024 | Dec 31, 2022 | ($137.42M) | Mar 17, 2025 |
| FY2024 | Dec 31, 2021 | $97.73M | Mar 17, 2025 |
| FY2023 | Dec 31, 2020 | $280.97M | Mar 15, 2024 |
| FY2022 | Dec 31, 2019 | $105.21M | Mar 6, 2023 |
| FY2021 | Dec 31, 2018 | ($38.59M) | Feb 23, 2022 |
| FY2020 | Dec 31, 2017 | $30.54M | Feb 25, 2021 |
| FY2017 | Dec 31, 2016 | $20.53M | Mar 8, 2018 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2023 | $943.0K | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | $943.0K | Mar 15, 2024 |
| FY2022 | Dec 31, 2021 | $900.0K | Mar 6, 2023 |
| FY2021 | Dec 31, 2020 | $943.0K | Feb 23, 2022 |
| FY2020 | Dec 31, 2019 | $943.0K | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | $943.0K | Feb 27, 2020 |
| FY2018 | Dec 31, 2017 | $943.0K | Feb 28, 2019 |
| FY2017 | Dec 31, 2016 | $943.0K | Mar 8, 2018 |
| FY2016 | Dec 31, 2015 | $943.0K | Mar 14, 2017 |
| FY2015 | Dec 31, 2014 | $943.0K | Feb 29, 2016 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($1.38B) | Mar 9, 2026 |
| FY2025 | Dec 31, 2024 | ($1.55B) | Mar 9, 2026 |
| FY2024 | Dec 31, 2023 | ($1.58B) | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | ($1.34B) | Mar 15, 2024 |
| FY2022 | Dec 31, 2021 | ($1.05B) | Mar 6, 2023 |
| FY2021 | Dec 31, 2020 | ($762.75M) | Feb 23, 2022 |
| FY2020 | Dec 31, 2019 | ($895.00M) | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | ($984.83M) | Feb 27, 2020 |
| FY2018 | Dec 31, 2017 | ($775.49M) | Feb 28, 2019 |
| FY2017 | Dec 31, 2016 | ($537.32M) | Mar 8, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $88.88M | Mar 9, 2026 |
| FY2025 | Dec 31, 2024 | $125.99M | Mar 9, 2026 |
| FY2024 | Dec 31, 2023 | $102.89M | Mar 17, 2025 |
| FY2024 | Dec 31, 2022 | $63.55M | Mar 17, 2025 |
| FY2024 | Dec 31, 2021 | $417.20M | Mar 17, 2025 |
| FY2023 | Dec 31, 2020 | $541.16M | Mar 15, 2024 |
| FY2022 | Dec 31, 2019 | $177.67M | Mar 6, 2023 |
| FY2021 | Dec 31, 2018 | $72.36M | Feb 23, 2022 |
| FY2019 | Dec 31, 2017 | $126.91M | Feb 27, 2020 |
| FY2017 | Dec 31, 2016 | $124.95M | Mar 8, 2018 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 1 | Mar 9, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 9, 2026 |
| FY2024 | Dec 31, 2023 | (2) | Mar 17, 2025 |
| FY2024 | Dec 31, 2022 | (3) | Mar 17, 2025 |
| FY2023 | Dec 31, 2021 | (3) | Mar 15, 2024 |
| FY2022 | Dec 31, 2020 | 1 | Mar 6, 2023 |
| FY2019 | Dec 31, 2019 | 0 | Feb 27, 2020 |
| FY2019 | Sep 30, 2019 | 0 | Feb 27, 2020 |
| FY2019 | Jun 30, 2019 | 0 | Feb 27, 2020 |
| FY2019 | Mar 31, 2019 | 0 | Feb 27, 2020 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 1 | Mar 9, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 9, 2026 |
| FY2024 | Dec 31, 2023 | (2) | Mar 17, 2025 |
| FY2024 | Dec 31, 2022 | (3) | Mar 17, 2025 |
| FY2023 | Dec 31, 2021 | (3) | Mar 15, 2024 |
| FY2022 | Dec 31, 2020 | 1 | Mar 6, 2023 |
| FY2019 | Dec 31, 2019 | 0 | Feb 27, 2020 |
| FY2019 | Sep 30, 2019 | 0 | Feb 27, 2020 |
| FY2019 | Jun 30, 2019 | 0 | Feb 27, 2020 |
| FY2019 | Mar 31, 2019 | 0 | Feb 27, 2020 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 121.15M | Mar 9, 2026 |
| FY2025 | Dec 31, 2024 | 115.61M | Mar 9, 2026 |
| FY2024 | Dec 31, 2023 | 112.22M | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | 78.85M | Mar 15, 2024 |
| FY2022 | Dec 31, 2021 | 76.93M | Mar 6, 2023 |
| FY2021 | Dec 31, 2020 | 72.51M | Feb 23, 2022 |
| FY2020 | Dec 31, 2019 | 70.37M | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | 68.30M | Feb 27, 2020 |
| FY2018 | Dec 31, 2017 | 59.84M | Feb 28, 2019 |
| FY2017 | Dec 31, 2016 | 45.81M | Mar 8, 2018 |